Reintroducing Foods After Completing Restrictive Low FODMAP Diet Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus), Gastroenterology Section, John D.…
Quality Indicators for Colonoscopy: New Targets… But Will They Be Measured?
Quality Indicators for Colonoscopy: New Targets… But Will They Be Measured? Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus), Gastroenterology…
Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol!
Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol! Nicole E. Rich, MD, MSCS Assistant Professor, Associate Director of the Liver…
A PPI a Day Keeps the GI Bleed Away in the ICU
A PPI a Day Keeps the GI Bleed Away in the ICU Philip N. Okafor, MD, MPH Senior Associate Consultant,…
A Laser Ruler to Hit the Mark on Polyp Size
A Laser Ruler To Hit The Mark On Polyp Size Timothy Yen, MD Assistant Professor of Medicine, Division of Gastroenterology,…
ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change?
ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change? Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus),…
Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm
Risankizumab Is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm Rahul…
Standardized Training for Endoscopic Mucosal Resection of Large Polyps: Does it Reduce Recurrence?
Standardized Training for Endoscopic Mucosal Resection of Large Polyps: Does it Reduce Recurrence? Ahmad Abu-Heija, MBBS Consultant Gastroenterologist, Oak…
Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring for Evaluation of Chronic Laryngeal Symptoms
Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring for Evaluation of Chronic Laryngeal Symptoms Swathi Eluri, MD, MSCR…
Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial
Risankizumab Is Superior to Ustekinumab for Induction and Maintenance of Crohn’s Disease: The SEQUENCE Trial Sara Ghoneim, MD1 and Bharati…
